Downloaded and translated from google news:"Tradingsat.com: What...

Downloaded and translated from google news:


"Tradingsat.com: What are your favorite biotech values in Europe and France in particular?

Guillaume Charbonnier: The selection of values occurs primarily targeting diseases. Today, 30% of target molecules developed cancer, 20% infectious diseases, 8% cardiovascular diseases, 7% of the autoimmune diseases and 6% in neurological disease. Transgene, Working on therapeutic vaccines for the treatment of various cancers, is logically one of the main lines of our portfolio. Also in France, positions have also been incorporated in Cellectis, Innate Pharma, Genfit... In the United Kingdom, a company like Antisoma great interest to us also. Another example is German securities as MediGene or 4 SC.

Tradingsat.com: After a surge of 75% in 2009, the share price of Transgene there still potential?

Guillaume Charbonnier: With good management, we have recently benefited in January of renewed speculation about the signing of a partnership for the TG4010 to take a small portion of our profits on value. The TG4010 is a therapeutic vaccine against lung cancer non-small cell. Waiting on an agreement with a major pharmaceutical company has extended, but it should not drag on. Transgene will probably participate in future product sales. This is interesting because the mechanism of action of TG4010 can be considered for use in treating other types of cancer: prostate, breast, kidney, etc. ...
"